Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Rebecca Taub Sells 648 Shares

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Rebecca Taub sold 648 shares of the stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $335.24, for a total transaction of $217,235.52. Following the completion of the transaction, the chief marketing officer now directly owns 456,662 shares of the company’s stock, valued at approximately $153,091,368.88. The trade was a 0.14 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Rebecca Taub also recently made the following trade(s):

• On Friday, January 17th, Rebecca Taub sold 1,689 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $273.41, for a total value of $461,789.49.

Madrigal Pharmaceuticals Trading Down 5.2 %

NASDAQ MDGL opened at $310.92 on Tuesday. Madrigal Pharmaceuticals, Inc. has a one year low of $168.25 and a one year high of $368.29. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. The company has a market capitalization of $6.78 billion, a price-to-earnings ratio of -12.40 and a beta of -0.36. The company’s 50-day simple moving average is $314.37 and its two-hundred day simple moving average is $273.95.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.94) by $2.02. The business had revenue of $62.18 million for the quarter, compared to analysts’ expectations of $34.60 million. During the same period in the previous year, the business earned ($5.34) earnings per share. Equities analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on MDGL. JMP Securities reissued a “market outperform” rating and set a $427.00 target price on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Oppenheimer reduced their target price on shares of Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 20th. B. Riley upped their price target on shares of Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, HC Wainwright raised their price objective on shares of Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $351.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Braidwell LP bought a new stake in Madrigal Pharmaceuticals during the third quarter valued at about $39,010,000. Eagle Asset Management Inc. bought a new stake in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at about $6,875,000. Intech Investment Management LLC bought a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter worth approximately $1,280,000. Vestal Point Capital LP bought a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter worth approximately $6,367,000. Finally, Blueshift Asset Management LLC purchased a new stake in Madrigal Pharmaceuticals during the third quarter valued at approximately $393,000. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.